Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 120, Issue 3, 2017, Pages 359-361

  Badreldin, Hisham A ^a   Carter, Danielle ^a   Cook, Bryan M ^a   Qamar, Arman ^a   Vaduganathan, Muthiah ^a   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; HEPARIN; TICAGRELOR; ADENOSINE; ADENOSINE PHOSPHATE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; TERTIARY CARE CENTER; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG TOLERANCE; EPIDEMIOLOGY; FOLLOW UP; HOSPITAL MORTALITY; INTRAVENOUS DRUG ADMINISTRATION; MASSACHUSETTS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MASSACHUSETTS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85019736408     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.04.034     Document Type: Article

References (10)

1. Bhatt, D.L., Lincoff, A.M., Gibson, C.M., Stone, G.W., McNulty, S., Montalescot, G., Kleiman, N.S., Goodman, S.G., White, H.D., Mahaffey, K.W., Pollack, C.V. Jr., Manoukian, S.V., Widimsky, P., Chew, D.P., Cura, F., Manukov, I., Tousek, F., Jafar, M.Z., Arneja, J., Skerjanec, S., Harrington, R.A., Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009), 2330–2341.
2. Bhatt, D.L., Stone, G.W., Mahaffey, K.W., Gibson, C.M., Steg, P.G., Hamm, C.W., Price, M.J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P.W., Widimsky, P., Tousek, F., Tauth, J., Spriggs, D., McLaurin, B.T., Angiolillo, D.J., Genereux, P., Liu, T., Prats, J., Todd, M., Skerjanec, S., White, H.D., Harrington, R.A., Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
3. Harrington, R.A., Stone, G.W., McNulty, S., White, H.D., Lincoff, A.M., Gibson, C.M., Pollack, C.V. Jr., Montalescot, G., Mahaffey, K.W., Kleiman, N.S., Goodman, S.G., Amine, M., Angiolillo, D.J., Becker, R.C., Chew, D.P., French, W.J., Leisch, F., Parikh, K.H., Skerjanec, S., Bhatt, D.L., Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009), 2318–2329.
4. Vaduganathan, M., Qamar, A., Singh, A., Venkateswaran, R.V., Szumita, P.M., Croce, K.J., Mauri, L., Leopold, J.A., Shah, P.B., Sobieszczyk, P., Faxon, D.P., Bhatt, D.L., Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital. J Am Coll Cardiol 69 (2017), 463–464.
5. Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
6. Hochholzer, W., Kleiner, P., Younas, I., Valina, C.M., Loffelhardt, N., Amann, M., Bomicke, T., Ferenc, M., Hauschke, D., Trenk, D., Neumann, F.J., Stratz, C., Randomized comparison of oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 trial. JACC Cardiovasc Interv 10 (2017), 121–129.
7. Gutierrez, J.A., Harrington, R.A., Blankenship, J.C., Stone, G.W., Steg, P.G., Gibson, C.M., Hamm, C.W., Price, M.J., Genereux, P., Prats, J., Deliargyris, E.N., Mahaffey, K.W., White, H.D., Bhatt, D.L., The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J 37 (2016), 1122–1130.
8. Vaduganathan, M., Harrington, R.A., Stone, G.W., Deliargyris, E.N., Steg, P.G., Gibson, C.M., Hamm, C.W., Price, M.J., Menozzi, A., Prats, J., Elkin, S., Mahaffey, K.W., White, H.D., Bhatt, D.L., Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory analysis from the CHAMPION trials. JAMA Cardiol 2 (2017), 127–135.
9. Vaduganathan, M., Harrington, R.A., Stone, G.W., Deliargyris, E.N., Steg, P.G., Gibson, C.M., Hamm, C.W., Price, M.J., Menozzi, A., Prats, J., Elkin, S., Mahaffey, K.W., White, H.D., Bhatt, D.L., Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 69 (2017), 176–185.
10. Kelly, C.R., Kirtane, A.J., Stant, J., Stone, G.W., Minutello, R.M., Wong, S.C., Manuzon, H., Gerow-Smith, R., Kelley, N., Rabbani, L.E., An updated protocol for evaluating chest pain and managing acute coronary syndromes. Crit Pathw Cardiol 16 (2017), 7–14.